Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Semaglutide. | Image Credit: K KStock - stock.adobe.com
Semaglutide Linked to Lower Dementia Risk in Type 2 Diabetes

June 24th 2025

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

Type 2 diabetes - greenapple78 - stock.adobe.com
Previsit Tools Boost Diabetes Deprescribing in Older Adults, Study Finds

June 23rd 2025

Diabetic man | Image credit: Krakenimages.com - stock.adobecom
Addressing Barriers to Hispanic Men's Engagement in Diabetes Prevention

June 18th 2025

Liver disease | Image credit: Crystal light - stock.adobe.com
Fatty Liver Found in Half of Patients With Type 2 Diabetes, Study Finds

June 13th 2025

DASH diet | Image credit: Albi - stock.adobe.com
DASH-Style Diet Lowers Blood Pressure in Type 2 Diabetes

June 10th 2025

Advancing Care in Type 2 Diabetes and Obesity: A Coordinated, Guideline-Driven Approach

Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.

AJMC Peer Exchange geometric background
Continuing Medical Education
View All
July 2nd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 2nd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

The top 5 diabetes content of 2024
December 16th 2024

Top 5 Most-Viewed Diabetes Content of 2024

Hayden E. Klein
This year’s top diabetes content focused on pediatric metabolic health, misconceptions about weight loss drugs, and more.
Doctor measuring patient's blood pressure | Image credit: Andrey Popov – stock.adobe.com
November 19th 2024

Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes

Connor Iapoce
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Young man frustrated with finances | Image credit: master1305 – stock.adobe.com
November 14th 2024

Young Adults With Low Incomes Have Higher Diabetes Mortality Risk

Hayden E. Klein
Young adults with type 2 diabetes and lower incomes face significantly higher mortality risks, highlighting socioeconomic disparities in health outcomes.
Diabetes | Image credit: Minerva Studio - stock.adobe.com.jpg
November 13th 2024

Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers

Elzbieta Dziekonski, RN
Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
AJMC Q&A with Dr Sanjula Jain | Background image credit: ipopba – stock.adobe.com
November 5th 2024

Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?

Hayden E. Klein
Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.
Aerial shot of neighborhood | Image credit: trekandphoto – stock.adobe.com
October 18th 2024

How Neighborhood Social Needs Drive Diabetes Care Disparities

Hayden E. Klein
Unmet social needs in certain neighborhoods contribute to disparities in diabetes care, leading to greater reliance on emergency services, fewer preventive measures, and higher rates of complications.
Lifestyle and dietary changes have proven benefits for patients with diabetes, sometimes eliminating the need for their medications | image credit: Africa Studio - stock.adobe.com
October 8th 2024

The Off-Ramp: Novel Diabetes Reversal Program Bolsters Support of Nonpharmacological Disease Management

Kyle Munz
Recent results from a new diabetes reversal program demonstrate the reliable, sustained benefits of nonpharmacological interventions in the management of diabetes and overall health of patients.
Diabetes | Image credit: Sherry Young – stock.adobe.com
October 1st 2024

What the Diabetes Health Economy Looks Like in 2024

Hayden E. Klein
The 2024 Trends Shaping the Health Economy report gave a past, present, and future look at diabetes care in the US and the role of obesity in these trends.
Senate. | Image Credit: Corgarashu - stock.adobe.com
September 24th 2024

Semaglutide Accessibility and Affordability Addressed at Senate Committee Hearing

Cameron Santoro
The Senate HELP Committee held a hearing to address the high cost of semaglutide drugs, finding that many patients cannot afford them despite their potential benefits.
Gavel and money | Image credit: BillionPhotos.com - stock.adobe.com
September 20th 2024

FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs

Skylar Jeremias
The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.
AJMC
September 5th 2024

Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes

Keith A. Betts, PhD Nikolaus G. Oberprieler, PhD, MSc, MBA Aozhou Wu, PhD Glen James, PhD Scott Beeman, PharmD Alain Gay, MD Xuanhao He, PhD David Vizcaya, PhD, MPH
This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.
Hot dogs with ketchup and mustard | Image credit: Mediteraneo – stock.adobe.com
September 4th 2024

Meat Consumption and Increased Diabetes Risk: Building on the Current Evidence Base

Hayden E. Klein
New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.
CGM | Image credit: Andrey Popov – stock.adobe.com
Published: August 27th 2024 | Updated: August 27th 2024

FDA Expands Omnipod 5 AID System Label to Treat Type 2 Diabetes

Hayden E. Klein
The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.
Red, yellow, and green trees reflecting memory loss or recovery | Image credit: freshidea – stock.adobe.com
August 27th 2024

SGLT2 Inhibitors, GLP-1 Agonists Similarly Reduce Dementia Risk for Patients With Diabetes

Hayden E. Klein
New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.
Jose A. Martinez, MD
August 20th 2024

Choosing the Right Treatment Path for Diabetic Macular Edema

Hayden E. Klein
Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach.
Using Telemedicine to Expand Diabetic Retinopathy Screening
August 16th 2024

Using Telemedicine to Expand Diabetic Retinopathy Screening

Hayden E. Klein
Despite guidelines recommending annual screenings, nearly half of patients with diabetes miss critical eye exams, explains Jose A. Martinez, MD, president and retina specialist at Austin Retina Associates.
AJMC
August 7th 2024

Adherence Patterns 1 Year After Initiation of SGLT2 Inhibitors: Results of a National Cohort Study

Hsiao-Ching Huang, PhD Daniel R. Touchette, PharmD, MA Mina Tadrous, PhD Glen T. Schumock, PharmD, PhD, MBA Saria Awadalla, PhD Todd A. Lee, PhD
This article describes the trajectory of adherence patterns among users of sodium-glucose cotransporter 2 (SGLT2) inhibitors. The authors found that baseline factors were unable to predict the adherence trajectory groups.
What We’re Reading: Ozempic Linked to Lower Tobacco-Related Health Care Use; Medical Debt Relief Plan in North Carolina; Nearly 1 in 4 US Adults Face Mental Health Care Barrier
July 30th 2024

What We’re Reading: Ozempic and Smoking Cessation; North Carolina’s Medical Debt Relief Plan; Mental Health Care Barriers

AJMC Staff
Smokers with diabetes on Ozempic are less likely to receive smoking cessation interventions; initiative incentivizes hospitals to eliminate medical debt for low- and middle-income patients; high costs prevent mental health treatment.
Older woman sleeping with clock on nightstand | Image credit: Pixel-Shot – stock.adobe.com
July 17th 2024

Inconsistent Sleep May Heighten Older Adults’ Risk of Diabetes

Hayden E. Klein
Older adults with the most irregular sleep durations demonstrated a 34% higher risk of developing type 2 diabetes compared with those with the most regular sleep.
What We’re Reading: Change Cyberattack Exposes Personal Data; Ozempic May Reduce Dementia Risk; Rural Hospitals Shutdown
July 15th 2024

What We’re Reading: Cyberattack Exposes Personal Data; Semaglutide May Reduce Dementia Risk; Rural Hospitals Shutdown

AJMC Staff
Up to one-third of Americans have been affected by data stolen through the Change Healthcare cyberattack; research highlights potential cognitive and psychiatric benefits of semaglutide; over 40 Iowa hospitals have ended their labor and delivery services.
what we're reading logo
July 10th 2024

What We’re Reading: CMS Dementia Care Program; Physician Burnout Drops; Impact of GLP-1 Shortages

AJMC Staff
CMS recently launched a voluntary, nationwide dementia care program; the number of physicians who reported at least 1 symptom of burnout has dropped below 50% for the first time since the onset of the COVID-19 pandemic; diabetes drugs have all been in short supply over the last 18 months, partly due to people using them off label for weight loss.
Doctor and patient discussing treatment plan | Image credit: Halfpoint – stock.adobe.com
July 5th 2024

GLP-1 Agonists May Reduce Cancer Risk for Patients With Diabetes

Hayden E. Klein
Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did.
Ian Neeland, MD
June 21st 2024

Obesity Management in 2024: A Look at the CINEMA Program’s Growth and Impact

Hayden E. Klein
The University Hospitals CINEMA program aims to address issues and narrow gaps in obesity management, with a focus on meeting patients where they are and providing them tools for success, says Ian Neeland, MD.
Robert Lustig, MD, MSL
June 21st 2024

Dr Robert Lustig on Pediatric Metabolic Health: “Sugar Is the Alcohol of the Child”

Hayden E. Klein
Robert Lustig, MD, MSL, explains how the US health care industry needs to shift from measuring body mass index and obesity to measuring cardiometabolic health, which affects 93% of Americans, including children.
What We’re Reading: Change Healthcare Warns of Massive Data Breach; Early Gestational Diabetes Screening; Bird Flu Testing Delays
June 21st 2024

What We’re Reading: Change Healthcare to Send Data Breach Warnings; Early Gestational Diabetes Screening; Bird Flu Testing Delays

AJMC Staff
Change Healthcare will begin notifying individuals whose data may have been exposed when hackers disrupted the claims processing system; experts advocate for early diagnosis of gestational diabetes to mitigate risks for both mother and child; researchers worry that the slow rollout of bird flu tests may hinder outbreak detection and response.
Ozempic | Image credit: mbruxelle – stock.adobe.com
June 20th 2024

WHO Issues Warning for Fake Semaglutide

Hayden E. Klein
Taking falsified semaglutide (Ozempic; Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning.
Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson
June 18th 2024

Age, Insurance Play Major Roles in CGM Use, Says Dr Chase Hendrickson

Hayden E. Klein
Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.
FDA | Image credit: Araki Illustrations – stock.adobe.com
June 13th 2024

FDA Approves Dapagliflozin for Children With Type 2 Diabetes

Hayden E. Klein
Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.
Semaglutide injections | Image credit: Patrick Bay Damsted – stock.adobe.com
May 24th 2024

Semaglutide Lowers Risk of Major Kidney Outcomes, Cardiovascular Events, Death in Patients With Diabetes and CKD

Hayden E. Klein
Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.
Supply of tirzepatide | Image credit: MKPhoto – stock.adobe.com
May 16th 2024

Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs

Hayden E. Klein
Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.
<12345678
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo